Skip to main content
Top
Published in: Cancer Cell International 1/2014

Open Access 01-12-2014 | Primary research

The involvement of miR-100 in bladder urothelial carcinogenesis changing the expression levels of mRNA and proteins of genes related to cell proliferation, survival, apoptosis and chromosomal stability

Authors: Denis R Morais, Sabrina T Reis, Nayara Viana, Camila Berfort Piantino, Cristina Massoco, Caio Moura, Nelson Dip, Iran A Silva, Miguel Srougi, Katia RM Leite

Published in: Cancer Cell International | Issue 1/2014

Login to get access

Abstract

Introduction

MicroRNAs (miRNA) are small non-coding RNAs that play an important role in the control of gene expression by inhibiting protein translation or promoting messenger RNA degradation. Today, miRNAs have been shown to be involved in various physiological and pathological cellular processes, including cancer, where they can act as oncogenes or tumor suppressor genes. Recently, lowered expression of miR-100, resulting in upregulation of FGFR3, has been correlated with low-grade, non-invasive bladder urothelial cancer, as an alternative oncogenesis pathway to the typical FGFR3 gene mutation. Our aim is to analyze the role of miR-100 in bladder cancer cell lines in controlling the expression of some of its possible target genes, including FGFR3 and its relationship with proliferation, apoptosis and DNA ploidy.

Methods

The bladder cancer cell lines RT4 and T24 were transfected with pre-miR 100, anti-miR 100 and their respective controls using a lipid-based formulation. After transfection mRNA and protein levels of its supposed target genes THAP2, BAZ2A, mTOR, SMARCA5 and FGFR3 were analyzed by quantitative real time polymerase chain reaction (qRT-PCR) and western blotting. Cell proliferation, apoptosis and DNA ploidy were analyzed by flow cytometry. For statistical analysis, a t-test was applied, p < 0.05 was considered significant.

Results

After miR-100 transfection, there was a significant reduction in the mRNA of mTOR (p = 0.006), SMARCA5 (p = 0.007) and BAZ2A (p = 0.029) in RT4, mTOR (p = 0.023) and SMARCA5 (p = 0.015) in T24. There was a reduction in the expression of all proteins, variable from 22.5% to 57.1% in both cell lines. In T24 miR-100 promoted an increase in cell proliferation and anti-miR 100 promoted apoptosis characterizing miR-100 as an oncomiR in this cell line representative of a high-grade urothelial carcinoma.

Conclusion

miR-100 transfection reduces expression of BAZ2A, mTOR and SMARCA5 mRNA and protein in BC cell lines. miR-100 would be classified as an oncomiR in T24 cells representative of high grade urothelial carcinoma promoting increase in cell proliferation and reduction in apoptosis. The knowledge of miRNA role in tumors will allow their use as tumor markers and targets for new therapies.
Appendix
Available only for authorised users
Literature
2.
go back to reference Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A, Enright AJ: miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res. 2006, 34: D140-D144. 10.1093/nar/gkj112.CrossRefPubMedCentralPubMed Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A, Enright AJ: miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res. 2006, 34: D140-D144. 10.1093/nar/gkj112.CrossRefPubMedCentralPubMed
3.
go back to reference Friedman RC, Farh KKH, Burge CB, Bartel DP: Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2009, 19 (1): 92-105. 10.1101/gr.082701.108.CrossRefPubMedCentralPubMed Friedman RC, Farh KKH, Burge CB, Bartel DP: Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2009, 19 (1): 92-105. 10.1101/gr.082701.108.CrossRefPubMedCentralPubMed
4.
go back to reference Esteller M: Non-coding RNAs in human disease. Nat Rev Genet. 2011, 12 (12): 861-874. 10.1038/nrg3074.CrossRefPubMed Esteller M: Non-coding RNAs in human disease. Nat Rev Genet. 2011, 12 (12): 861-874. 10.1038/nrg3074.CrossRefPubMed
5.
go back to reference Nelson Dip STR, Timoszczuk LS, Daniel Kanda A, Marcos D'O, Miguel S, Katia RM L: Under-expression of miR-100 may be a new Carcinogenic pathway for low-grade pTa Bladder Urothelial Carcinomas. J Mol Biomarkers Diagnosis. 2012, 3 (1): 1-3. Nelson Dip STR, Timoszczuk LS, Daniel Kanda A, Marcos D'O, Miguel S, Katia RM L: Under-expression of miR-100 may be a new Carcinogenic pathway for low-grade pTa Bladder Urothelial Carcinomas. J Mol Biomarkers Diagnosis. 2012, 3 (1): 1-3.
6.
go back to reference Wong TS, Liu XB, Wong BYH, Ng RWM, Yuen APW, Wei WI: Mature miR-184 as potential oncogenic microRNA of squamous cell carcinoma of tongue. Clin Cancer Res. 2008, 14 (9): 2588-2592. 10.1158/1078-0432.CCR-07-0666.CrossRefPubMed Wong TS, Liu XB, Wong BYH, Ng RWM, Yuen APW, Wei WI: Mature miR-184 as potential oncogenic microRNA of squamous cell carcinoma of tongue. Clin Cancer Res. 2008, 14 (9): 2588-2592. 10.1158/1078-0432.CCR-07-0666.CrossRefPubMed
7.
go back to reference Henson BJ, Bhattacharjee S, O'Dee DM, Feingold E, Gollin SM: Decreased Expression of miR-125b and miR-100 in Oral Cancer Cells Contributes to Malignancy. Genes Chromosomes & Cancer. 2009, 48 (7): 569-582. 10.1002/gcc.20666.CrossRef Henson BJ, Bhattacharjee S, O'Dee DM, Feingold E, Gollin SM: Decreased Expression of miR-125b and miR-100 in Oral Cancer Cells Contributes to Malignancy. Genes Chromosomes & Cancer. 2009, 48 (7): 569-582. 10.1002/gcc.20666.CrossRef
8.
go back to reference Shi W, Alajez NM, Bastianutto C, Hui ABY, Mocanu JD, Ito E, Busson P, Lo KW, Ng R, Waldron J, O'Sullivan B, Liu FF: Significance of Plk1 regulation by miR-100 in human nasopharyngeal cancer. Int J Cancer. 2010, 126 (9): 2036-2048.PubMed Shi W, Alajez NM, Bastianutto C, Hui ABY, Mocanu JD, Ito E, Busson P, Lo KW, Ng R, Waldron J, O'Sullivan B, Liu FF: Significance of Plk1 regulation by miR-100 in human nasopharyngeal cancer. Int J Cancer. 2010, 126 (9): 2036-2048.PubMed
9.
go back to reference Petrelli A, Perra A, Schernhuber K, Cargnelutti M, Salvi A, Migliore C, Ghiso E, Benetti A, Barlati S, Ledda-Columbano GM, Portolani N, De Petro G, Columbano A, Giordano S: Sequential analysis of multistage hepatocarcinogenesis reveals that miR-100 and PLK1 dysregulation is an early event maintained along tumor progression. Oncogene. 2012, 31 (42): 4517-4526. 10.1038/onc.2011.631.CrossRefPubMed Petrelli A, Perra A, Schernhuber K, Cargnelutti M, Salvi A, Migliore C, Ghiso E, Benetti A, Barlati S, Ledda-Columbano GM, Portolani N, De Petro G, Columbano A, Giordano S: Sequential analysis of multistage hepatocarcinogenesis reveals that miR-100 and PLK1 dysregulation is an early event maintained along tumor progression. Oncogene. 2012, 31 (42): 4517-4526. 10.1038/onc.2011.631.CrossRefPubMed
10.
go back to reference Cairo S, Wang YP, de Reynies A, Duroure K, Dahan J, Redon MJ, Fabre M, McClelland M, Wang XW, Croce CM, Buendia MA: Stem cell-like micro-RNA signature driven by Myc in aggressive liver cancer. P Natl Acad Sci USA. 2010, 107 (47): 20471-20476. 10.1073/pnas.1009009107.CrossRef Cairo S, Wang YP, de Reynies A, Duroure K, Dahan J, Redon MJ, Fabre M, McClelland M, Wang XW, Croce CM, Buendia MA: Stem cell-like micro-RNA signature driven by Myc in aggressive liver cancer. P Natl Acad Sci USA. 2010, 107 (47): 20471-20476. 10.1073/pnas.1009009107.CrossRef
11.
go back to reference Nam EJ, Yoon HJ, Kim SW, Kim HG, Kim YT, Kim JH, Kim JW, Kim SH: MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res. 2008, 14 (9): 2690-2695. 10.1158/1078-0432.CCR-07-1731.CrossRefPubMed Nam EJ, Yoon HJ, Kim SW, Kim HG, Kim YT, Kim JH, Kim JW, Kim SH: MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res. 2008, 14 (9): 2690-2695. 10.1158/1078-0432.CCR-07-1731.CrossRefPubMed
12.
go back to reference Liu W, Gong YH, Chao TF, Peng XZ, Yuan JG, Ma ZY, Jia G, Zhao JZ: Identiflcation of differentially expressed microRNAs by microarray: a possible role for microRNAs gene in medulloblastomas. Chin Med J. 2009, 122 (20): 2405-2411.PubMed Liu W, Gong YH, Chao TF, Peng XZ, Yuan JG, Ma ZY, Jia G, Zhao JZ: Identiflcation of differentially expressed microRNAs by microarray: a possible role for microRNAs gene in medulloblastomas. Chin Med J. 2009, 122 (20): 2405-2411.PubMed
13.
go back to reference Ueda T, Volinia S, Okumura H, Shimizu M, Taccioli C, Rossi S, Alder H, Liu CG, Oue N, Yasui W, Yoshida K, Sasaki H, Nomura S, Seto Y, Kaminishi M, Calin GA, Croce CM: Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. Lancet Oncol. 2010, 11 (2): 136-146. 10.1016/S1470-2045(09)70343-2.CrossRefPubMedCentralPubMed Ueda T, Volinia S, Okumura H, Shimizu M, Taccioli C, Rossi S, Alder H, Liu CG, Oue N, Yasui W, Yoshida K, Sasaki H, Nomura S, Seto Y, Kaminishi M, Calin GA, Croce CM: Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. Lancet Oncol. 2010, 11 (2): 136-146. 10.1016/S1470-2045(09)70343-2.CrossRefPubMedCentralPubMed
14.
go back to reference Lee EJ, Gusev Y, Jiang JM, Nuovo GJ, Lerner MR, Frankel WL, Morgan DL, Postier RG, Brackett DJ, Schmittgen TD: Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer. 2007, 120 (5): 1046-1054. 10.1002/ijc.22394.CrossRefPubMedCentralPubMed Lee EJ, Gusev Y, Jiang JM, Nuovo GJ, Lerner MR, Frankel WL, Morgan DL, Postier RG, Brackett DJ, Schmittgen TD: Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer. 2007, 120 (5): 1046-1054. 10.1002/ijc.22394.CrossRefPubMedCentralPubMed
15.
go back to reference Leite KR, Tomiyama A, Reis ST, Sousa-Canavez JM, Sanudo A, Dall'Oglio MF, Camara-Lopes LH, Srougi M: MicroRNA-100 expression is independently related to biochemical recurrence of prostate cancer. J Urol. 2011, 185 (3): 1118-1122. 10.1016/j.juro.2010.10.035.CrossRefPubMed Leite KR, Tomiyama A, Reis ST, Sousa-Canavez JM, Sanudo A, Dall'Oglio MF, Camara-Lopes LH, Srougi M: MicroRNA-100 expression is independently related to biochemical recurrence of prostate cancer. J Urol. 2011, 185 (3): 1118-1122. 10.1016/j.juro.2010.10.035.CrossRefPubMed
16.
go back to reference Dip N, Reis ST, Timoszczuk LS, Viana NI, Piantino CB, Morais DR, Moura CM, Abe DK, Silva IA, Srougi M, Dall'Oglio MF, Leite KR: Stage, grade and behavior of bladder urothelial carcinoma defined by the microRNA expression profile. J Urol. 2012, 188 (5): 1951-1956. 10.1016/j.juro.2012.07.004.CrossRefPubMed Dip N, Reis ST, Timoszczuk LS, Viana NI, Piantino CB, Morais DR, Moura CM, Abe DK, Silva IA, Srougi M, Dall'Oglio MF, Leite KR: Stage, grade and behavior of bladder urothelial carcinoma defined by the microRNA expression profile. J Urol. 2012, 188 (5): 1951-1956. 10.1016/j.juro.2012.07.004.CrossRefPubMed
17.
go back to reference Song T, Xia W, Shao N, Zhang X, Wang C, Wu Y, Dong J, Cai W, Li H: Differential miRNA expression profiles in bladder urothelial carcinomas. APJCP. 2010, 11 (4): 905-911.PubMed Song T, Xia W, Shao N, Zhang X, Wang C, Wu Y, Dong J, Cai W, Li H: Differential miRNA expression profiles in bladder urothelial carcinomas. APJCP. 2010, 11 (4): 905-911.PubMed
18.
go back to reference Catto JW, Miah S, Owen HC, Bryant H, Myers K, Dudziec E, Larre S, Milo M, Rehman I, Rosario DJ, Di Martino E, Knowles MA, Meuth M, Harris AL, Hamdy FC: Distinct microRNA alterations characterize high- and low-grade bladder cancer. Cancer Res. 2009, 69 (21): 8472-8481. 10.1158/0008-5472.CAN-09-0744.CrossRefPubMedCentralPubMed Catto JW, Miah S, Owen HC, Bryant H, Myers K, Dudziec E, Larre S, Milo M, Rehman I, Rosario DJ, Di Martino E, Knowles MA, Meuth M, Harris AL, Hamdy FC: Distinct microRNA alterations characterize high- and low-grade bladder cancer. Cancer Res. 2009, 69 (21): 8472-8481. 10.1158/0008-5472.CAN-09-0744.CrossRefPubMedCentralPubMed
19.
go back to reference Rieger-Christ KM, Mourtzinos A, Lee PJ, Zagha RM, Cain J, Silverman M, Libertino JA, Summerhayes IC: Identification of fibroblast growth factor receptor 3 mutations in urine sediment DNA samples complements cytology in bladder tumor detection. Cancer. 2003, 98 (4): 737-744. 10.1002/cncr.11536.CrossRefPubMed Rieger-Christ KM, Mourtzinos A, Lee PJ, Zagha RM, Cain J, Silverman M, Libertino JA, Summerhayes IC: Identification of fibroblast growth factor receptor 3 mutations in urine sediment DNA samples complements cytology in bladder tumor detection. Cancer. 2003, 98 (4): 737-744. 10.1002/cncr.11536.CrossRefPubMed
20.
go back to reference Neuzillet Y, Paoletti X, Ouerhani S, Mongiat-Artus P, Soliman H, de The H, Sibony M, Denoux Y, Molinie V, Herault A, Lepage ML, Maille P, Renou A, Vordos D, Abbou CC, Bakkar A, Asselain B, Kourda N, El Gaaied A, Leroy K, Laplanche A, Benhamou S, Lebret T, Allory Y, Radvanyi F: A Meta-Analysis of the Relationship between FGFR3 and TP53 Mutations in Bladder Cancer. Plos One. 2012, 7 (12): e48993-10.1371/journal.pone.0048993.CrossRefPubMedCentralPubMed Neuzillet Y, Paoletti X, Ouerhani S, Mongiat-Artus P, Soliman H, de The H, Sibony M, Denoux Y, Molinie V, Herault A, Lepage ML, Maille P, Renou A, Vordos D, Abbou CC, Bakkar A, Asselain B, Kourda N, El Gaaied A, Leroy K, Laplanche A, Benhamou S, Lebret T, Allory Y, Radvanyi F: A Meta-Analysis of the Relationship between FGFR3 and TP53 Mutations in Bladder Cancer. Plos One. 2012, 7 (12): e48993-10.1371/journal.pone.0048993.CrossRefPubMedCentralPubMed
21.
go back to reference Garcia JA, Danielpour D: Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies. Mol Cancer Ther. 2008, 7 (6): 1347-1354. 10.1158/1535-7163.MCT-07-2408.CrossRefPubMedCentralPubMed Garcia JA, Danielpour D: Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies. Mol Cancer Ther. 2008, 7 (6): 1347-1354. 10.1158/1535-7163.MCT-07-2408.CrossRefPubMedCentralPubMed
22.
go back to reference Park SJ, Lee TJ, Chang IH: Role of the mTOR Pathway in the Progression and Recurrence of Bladder Cancer: An Immunohistochemical Tissue Microarray Study. Korean journal of urology. 2011, 52 (7): 466-473. 10.4111/kju.2011.52.7.466.CrossRefPubMedCentralPubMed Park SJ, Lee TJ, Chang IH: Role of the mTOR Pathway in the Progression and Recurrence of Bladder Cancer: An Immunohistochemical Tissue Microarray Study. Korean journal of urology. 2011, 52 (7): 466-473. 10.4111/kju.2011.52.7.466.CrossRefPubMedCentralPubMed
23.
go back to reference Xu C, Zeng Q, Xu W, Jiao L, Chen Y, Zhang Z, Wu C, Jin T, Pan A, Wei R, Yang B, Sun Y: miRNA-100 Inhibits Human Bladder Urothelial Carcinogenesis by Directly Targeting mTOR. Mol Cancer Ther. 2013, 12 (2): 207-219. 10.1158/1535-7163.MCT-12-0273.CrossRefPubMed Xu C, Zeng Q, Xu W, Jiao L, Chen Y, Zhang Z, Wu C, Jin T, Pan A, Wei R, Yang B, Sun Y: miRNA-100 Inhibits Human Bladder Urothelial Carcinogenesis by Directly Targeting mTOR. Mol Cancer Ther. 2013, 12 (2): 207-219. 10.1158/1535-7163.MCT-12-0273.CrossRefPubMed
24.
go back to reference Lan L, Ui A, Nakajima S, Hatakeyama K, Hoshi M, Watanabe R, Janicki SM, Ogiwara H, Kohno T, Kanno S, Yasui UMA: The ACF1 complex is required for DNA double-strand break repair in human cells. Mol Cell. 2010, 40 (6): 976-987. 10.1016/j.molcel.2010.12.003.CrossRefPubMed Lan L, Ui A, Nakajima S, Hatakeyama K, Hoshi M, Watanabe R, Janicki SM, Ogiwara H, Kohno T, Kanno S, Yasui UMA: The ACF1 complex is required for DNA double-strand break repair in human cells. Mol Cell. 2010, 40 (6): 976-987. 10.1016/j.molcel.2010.12.003.CrossRefPubMed
25.
go back to reference Havas K, Whitehouse I, Owen-Hughes T: ATP-dependent chromatin remodeling activities. Cell Mol Life Sci. 2001, 58 (5–6): 673-682. 10.1007/PL00000891.CrossRefPubMed Havas K, Whitehouse I, Owen-Hughes T: ATP-dependent chromatin remodeling activities. Cell Mol Life Sci. 2001, 58 (5–6): 673-682. 10.1007/PL00000891.CrossRefPubMed
26.
go back to reference Mueller AC, Sun D, Dutta A: The miR-99 family regulates the DNA damage response through its target SNF2H. Oncogene. 2013, 32 (9): 1164-1172. 10.1038/onc.2012.131.CrossRefPubMedCentralPubMed Mueller AC, Sun D, Dutta A: The miR-99 family regulates the DNA damage response through its target SNF2H. Oncogene. 2013, 32 (9): 1164-1172. 10.1038/onc.2012.131.CrossRefPubMedCentralPubMed
27.
go back to reference Bessiere D, Lacroix C, Campagne S, Ecochard V, Guillet V, Mourey L, Lopez F, Czaplicki J, Demange P, Milon A, Girard JP, Gervais V: Structure-function analysis of the THAP zinc finger of THAP1, a large C2CH DNA-binding module linked to Rb/E2F pathways. J Biol Chem. 2008, 283 (7): 4352-4363. 10.1074/jbc.M707537200.CrossRefPubMed Bessiere D, Lacroix C, Campagne S, Ecochard V, Guillet V, Mourey L, Lopez F, Czaplicki J, Demange P, Milon A, Girard JP, Gervais V: Structure-function analysis of the THAP zinc finger of THAP1, a large C2CH DNA-binding module linked to Rb/E2F pathways. J Biol Chem. 2008, 283 (7): 4352-4363. 10.1074/jbc.M707537200.CrossRefPubMed
28.
go back to reference Macfarlan T, Kutney S, Altman B, Montross R, Yu J, Chakravarti D: Human THAP7 is a chromatin-associated, histone tail-binding protein that represses transcription via recruitment of HDAC3 and nuclear hormone receptor corepressor. The Journal of biological chemistry. 2005, 280 (8): 7346-7358. 10.1074/jbc.M411675200.CrossRefPubMed Macfarlan T, Kutney S, Altman B, Montross R, Yu J, Chakravarti D: Human THAP7 is a chromatin-associated, histone tail-binding protein that represses transcription via recruitment of HDAC3 and nuclear hormone receptor corepressor. The Journal of biological chemistry. 2005, 280 (8): 7346-7358. 10.1074/jbc.M411675200.CrossRefPubMed
29.
go back to reference Roussigne M, Cayrol C, Clouaire T, Amalric F, Girard JP: THAP1 is a nuclear proapoptotic factor that links prostate-apoptosis-response-4 (Par-4) to PML nuclear bodies. Oncogene. 2003, 22 (16): 2432-2442. 10.1038/sj.onc.1206271.CrossRefPubMed Roussigne M, Cayrol C, Clouaire T, Amalric F, Girard JP: THAP1 is a nuclear proapoptotic factor that links prostate-apoptosis-response-4 (Par-4) to PML nuclear bodies. Oncogene. 2003, 22 (16): 2432-2442. 10.1038/sj.onc.1206271.CrossRefPubMed
30.
go back to reference Cayrol C, Lacroix C, Mathe C, Ecochard V, Ceribelli M, Loreau E, Lazar V, Dessen P, Mantovani R, Aguilar L, Girardi JP: The THAP-zinc finger protein THAP1 regulates endothelial cell proliferation through modulation of pRB/E2F cell-cycle target genes. Blood. 2007, 109 (2): 584-594. 10.1182/blood-2006-03-012013.CrossRefPubMed Cayrol C, Lacroix C, Mathe C, Ecochard V, Ceribelli M, Loreau E, Lazar V, Dessen P, Mantovani R, Aguilar L, Girardi JP: The THAP-zinc finger protein THAP1 regulates endothelial cell proliferation through modulation of pRB/E2F cell-cycle target genes. Blood. 2007, 109 (2): 584-594. 10.1182/blood-2006-03-012013.CrossRefPubMed
31.
go back to reference Knowles MA: Molecular pathogenesis of bladder cancer. Int J Clin Oncol. 2008, 13 (4): 287-297. 10.1007/s10147-008-0812-0.CrossRefPubMed Knowles MA: Molecular pathogenesis of bladder cancer. Int J Clin Oncol. 2008, 13 (4): 287-297. 10.1007/s10147-008-0812-0.CrossRefPubMed
32.
go back to reference Zhou Y, Santoro R, Grummt I: The chromatin remodeling complex NoRC targets HDAC1 to the ribosomal gene promoter and represses RNA polymerase I transcription. The EMBO journal. 2002, 21 (17): 4632-4640. 10.1093/emboj/cdf460.CrossRefPubMedCentralPubMed Zhou Y, Santoro R, Grummt I: The chromatin remodeling complex NoRC targets HDAC1 to the ribosomal gene promoter and represses RNA polymerase I transcription. The EMBO journal. 2002, 21 (17): 4632-4640. 10.1093/emboj/cdf460.CrossRefPubMedCentralPubMed
Metadata
Title
The involvement of miR-100 in bladder urothelial carcinogenesis changing the expression levels of mRNA and proteins of genes related to cell proliferation, survival, apoptosis and chromosomal stability
Authors
Denis R Morais
Sabrina T Reis
Nayara Viana
Camila Berfort Piantino
Cristina Massoco
Caio Moura
Nelson Dip
Iran A Silva
Miguel Srougi
Katia RM Leite
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2014
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-014-0119-3

Other articles of this Issue 1/2014

Cancer Cell International 1/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine